Drug-Eluting Beads versus Lipiodol Transarterial Chemoembolization for the Treatment of Hypovascular Hepatocellular Carcinoma: A Single-Center Retrospective Study

References

• Villanueva A, Longo DL. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra171326330970190
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Lee JM, Trevisani F, Vilgrain V, Wald C. Imaging diagnosis and staging of hepatocellular carcinoma. Liver Transpl. 2011;17(Suppl):2S34–S43. doi:10.1002/lt.22369
   Web of Science ®Google Scholar
• Maesaka K, Sakamori R, Yamada R, et al. Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma. Hepatol Res. 2020;50(3):365–373. doi:10.1111/hepr.1344631661722
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–370. doi:10.1007/s12072-017-9799-928620797
   PubMed Web of Science ®Google Scholar
• Iwazawa J, Ohue S, Mitani T, et al. Identifying feeding arteries during TACE of hepatic tumors: comparison of C-arm CT and digital subtraction angiography. AJR Am J Roentgenol. 2009;192(4):1057–1063. doi:10.2214/AJR.08.128519304714
   PubMed Web of Science ®Google Scholar
• Yang W, Yan K, Chen MH, et al. Preliminary experience with direct percutaneous arterial embolisation combined with radiofrequency ablation for hypervascular HCC. Int J Hyperthermia. 2017;33(7):836–845. doi:10.1080/02656736.2017.130512628540794
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Lee JC, Yang W, et al. Percutaneous ablation of the tumor feeding artery for hypervascular hepatocellular carcinoma before tumor ablation. Int J Hyperthermia. 2018;35(1):133–139. doi:10.1080/02656736.2018.148452529999436
   PubMed Web of Science ®Google Scholar
• Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol. 2016;25(2):74–85. doi:10.1016/j.suronc.2016.03.00227312032
   PubMed Web of Science ®Google Scholar
• Ha Y, Lee JB, Shim JH, et al. Validation and reappraisal of the assessment for retreatment with transarterial chemoembolization score for unresectable non-metastatic hepatocellular carcinoma in a hepatitis b virus-endemic region. Eur Radiol. 2016;26(10):3510–3518. doi:10.1007/s00330-015-4185-226747261
   PubMed Web of Science ®Google Scholar
• Aramaki T, Moriguchi M, Bekku E, Asakura K, Sawada A, Endo M. Comparison of epirubicin hydrochloride and miriplatin hydrate as anticancer agents for transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatol Res. 2013;43(5):475–480. doi:10.1111/j.1872-034X.2012.01100.x23046493
   PubMed Web of Science ®Google Scholar
• Shirono T, Iwamoto H, Niizeki T, et al. Epirubicin is more effective than miriplatin in balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. Oncology. 2019;96(2):79–86. doi:10.1159/00049282230293080
   PubMed Web of Science ®Google Scholar
• Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64(1):106–116. doi:10.1002/hep.2845326765068
   PubMed Web of Science ®Google Scholar
• Zhang S, Huang C, Li Z, et al. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers. Drug Deliv. 2017;24(1):1011–1017. doi:10.1080/10717544.2017.134433628660787
   PubMed Web of Science ®Google Scholar
• Aliberti C, Carandina R, Lonardi S, et al. Transarterial chemoembolization with small drug-eluting beads in patients with hepatocellular carcinoma: experience from a cohort of 421 patients at an Italian center. J Vasc Interv Radiol. 2017;28(11):1495–1502. doi:10.1016/j.jvir.2017.07.02028927662
   PubMed Web of Science ®Google Scholar
• Wu B, Zhou J, Ling G, Zhu D, Long Q. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. World J Surg Oncol. 2018;16(1):69. doi:10.1186/s12957-018-1368-829587773
   PubMedGoogle Scholar
• Zhou GH, Han J, Sun JH, et al. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients. BMC Cancer. 2018;18(1):644. doi:10.1186/s12885-018-4566-429914435
   PubMedGoogle Scholar
• Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46(3):474–481. doi:10.1016/j.jhep.2006.10.02017239480
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.01929628281
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi:10.1055/s-0030-124713220175033
   PubMed Web of Science ®Google Scholar
• Khalilzadeh O, Baerlocher MO, Shyn PB, et al. Proposal of a new adverse event classification by the society of interventional radiology standards of practice committee. J Vasc Interv Radiol. 2017;28(10):1432–1437 e1433. doi:10.1016/j.jvir.2017.06.01928757285
   PubMed Web of Science ®Google Scholar
• Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol. 2009;44(Suppl):19112–19118. doi:10.1007/s00535-008-2274-6
   Web of Science ®Google Scholar
• Murakami T, Ishimaru H, Sakamoto I, et al. Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence. Cardiovasc Intervent Radiol. 2007;30(4):696–704. doi:10.1007/s00270-007-9003-z17497071
   PubMed Web of Science ®Google Scholar
• Ogasawara S, Chiba T, Motoyama T, et al. Prognostic significance of concurrent hypovascular and hypervascular nodules in patients with hepatocellular carcinoma. PLoS One. 2016;11(9):e0163119. doi:10.1371/journal.pone.016311927649084
   PubMed Web of Science ®Google Scholar
• Huang K, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(5):920–925. doi:10.1111/jgh.1243924224722
   PubMed Web of Science ®Google Scholar
• Zhou X, Tang Z, Wang J, et al. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis. Int J Clin Exp Med. 2014;7(11):3892–3903.25550897
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhao C, Zhao H, et al. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients. Am J Transl Res. 2019;11(12):7456–7470.31934293
   PubMed Web of Science ®Google Scholar
• Nakano MM, Yamamoto A, Nishida N, et al. Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE). Jpn J Radiol. 2019;37(7):543–548. doi:10.1007/s11604-019-00840-431055710
   PubMed Web of Science ®Google Scholar
• Kudo M, Matsui O, Izumi N, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer. 2014;3(3–4):458–468. doi:10.1159/00034387526280007
   PubMed Web of Science ®Google Scholar
• Terzi E, Golfieri R, Piscaglia F, et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. J Hepatol. 2012;57(6):1258–1267. doi:10.1016/j.jhep.2012.07.02522871502
   PubMed Web of Science ®Google Scholar
• Choi J, Shim JH, Shin YM, Kim KM, Lim YS, Lee HC. Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma. J Hepatol. 2014;60(6):1212–1218. doi:10.1016/j.jhep.2014.01.01424486088
   PubMed Web of Science ®Google Scholar